0.869
-0.08 (-7.94%)
| Penutupan Terdahulu | 0.944 |
| Jumlah Dagangan | 81,301 |
| Harga / Buku (P/B) | 0.110 |
| Julat 52 Minggu |
| EPS Cair (TTM) | -1.12 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 1.56% |
| Nisbah Semasa (MRQ) | 1.75 |
| Aliran Tunai Operasi (OCF TTM) | -4.57 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -3.45 M |
| Pulangan Atas Aset (ROA TTM) | -52.23% |
| Pulangan Atas Ekuiti (ROE TTM) | -139.17% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Clearmind Medicine Inc. | - | - |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -0.5 |
| Purata | -1.07 |
|
Clearmind Medicine Inc is a clinical-stage pharmaceutical company engaged in Phase I/IIa clinical trials of novel psychedelic medicines. The Company focuses on developing treatments for mental health disorders, including alcohol use disorder (AUD), binge drinking, and eating disorders. Its activities are centered on the research and development of 5-methoxy-2-aminoindane (MEAI). It operates through a single research and development segment, which is conducted in Israel. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 2.80% |
| % Dimiliki oleh Institusi | 10.91% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |